Aiosyn

Company profile

About Aiosyn

Aiosyn is a computational pathology company that develops AI-powered software solutions for cancer and kidney disease diagnosis and research. Founded as a spin-off from Radboudumc in the Netherlands, the company combines over 20 years of research experience with state-of-the-art artificial intelligence and engineering to create precision pathology solutions. Aiosyn's technology analyzes whole slide images using deep learning algorithms to enhance diagnostic accuracy and efficiency in digital pathology workflows. The company offers three main product lines: AiosynQC for automated quality control of digital histology slides, Aiosyn Mitosis Breast for identifying mitotic figures in breast cancer H&E sections, and the NephroPath platform for precise quantification of kidney lesion scores. These solutions are tightly integrated into existing pathology workflows, ensuring seamless adoption without disrupting established processes. Aiosyn serves clinical diagnostics laboratories, biopharma organizations, CROs, and AI/data providers. For clinical labs, the company provides certified diagnostic algorithms that augment pathologists' capabilities. For life sciences organizations, Aiosyn supports drug development by identifying novel pathology-based biomarkers and streamlining review processes. The company's modular software approach and close collaboration with pathology laboratories enable co-development of solutions that address real-world clinical needs while improving patient outcomes worldwide.

Company description · Aiosyn official website